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A cDNA probe for the low density lipoprotein (LDL) receptor gene was used to screen DNA samples from 52 unrelated 
Finnish patients with the heterozygous form of familial hypercholesterolemia (FH) and 51 healthy controls. Southern 
blot analysis using the restriction enzyme PvuII revealed an abnormal 11 kb (kilo base-pair) restriction fragment in 16 
(31%) of the patients but none of the controls. A more detailed restriction enzyme analysis of the DNA from patients 
revealed a mutation which apparently is due to an 8 kb deletion extending from intron 15 to exon 18 of the LDL receptor 
gene. Co-segregation of FH with the mutated gene was demonstrated in three families. These data are consistent with 
a ‘founder gene effect’ and support the assumption that recombinant DNA methods may have great impact on the diag- 
nostics of FH in genetically homogeneous populations. 
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1. INTRODUCTION 
Mutations of the LDL receptor gene give rise to 
familial hypercholesterolemia (FH), a disease 
characterized by elevated levels of serum LDL, 
tendon xanthomata and premature atherosclerosis 
[1,2]. The disease is inherited in an autosomal 
dominant fashion and is relatively common: about 
one in every 500 persons is heterozygous for the 
mutant allele of the LDL receptor gene [I]. These 
patients, untreated males especially, frequently 
undergo myocardial infarction below 50 years of 
age [3], while the rare FH patients homozygous for 
a defective allele suffer from symptoms of cor- 
onary heart disease from childhood on. 
Recombinant DNA techniques have greatly aid- 
ed in the understanding of the molecular genetics 
of FH. Isolation of cloned DNA sequences cor- 
responding to the LDL receptor mRNA [4] and the 
structural gene [5] has demonstrated that the LDL 
Correspondence address: K. Kontula, Recombinant DNA 
Laboratory, University of Helsinki, Valimotie 7, SF-00380 
Helsinki, Finland 
receptor gene resides in chromosome 19 [6], spann- 
ing approx. 45 kb (kilo base-pairs) with 18 exons 
and 17 introns. The availability of cloned gene 
probes has enabled the analysis of LDL receptor 
gene mutations at the DNA level. Russell et al. 
[2,6-151 have characterized some 15 mutations 
which include single-base substitutions, small and 
large insertions, exon duplications and large dele- 
tions. Heterogeneity at the DNA level undoubtedly 
hampers approaches for molecular genetic 
diagnostics of FH. The situation may be different 
in populations with a relatively homogenous 
genetic background [12,15,16]. We examined 
possible gross mutations of the LDL receptor gene 
among Finns who form a genetic isolate and have 
a coronary heart disease mortality rate which is 
among the highest in the world. 
2. MATERIALS AND METHODS 
2.1. Subjects 
A cohort of 52 patients with the heterozygous form of FH 
was studied. The diagnostic criteria included (i) the presence of 
hypercholesterolemia in at least one of the first-degree relatives, 
(ii) serum total cholesterol level > 8 mmol/l and/or serum LDL 
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cholesterol level > 6 mmol/l and (iii) tendon xanthomas. There 
were 16 men (aged 32-63 years) and 36 women (aged 15-69 
years). 51 normolipemic, apparently healthy subjects (25 males, 
26 females) served as controls. All patients and controls studied 
were unrelated and of Finnish origin. 
2.2. DNA analysis 
DNA was prepared from leukocytes obtained from 20 ml of 
venous blood essentially as described [17]. DNA (5-10 pg) was 
digested with the appropriate restriction enzymes (BarnHI, 
EcoRV, NcoI, PvuII, XbaI) using conditions recommended by 
the manufacturers, fractionated by gel electrophoresis on 0.6% 
agarose and transferred to nitrocellulose filters. Hybridization 
of the filter-bound DNA was carried out in a medium contain- 
ing 6 x SSC (1 x SSC: 0.15 M NaCl/O.OlS M trisodium 
citrate), 5 x Denhardt’s solution, 50% deionized formamide, 
0.25% SDS, lOO,~g/ml salmon sperm DNA and l-2 x 
lo6 cpm/ml of “P-1abelled LDL receptor gene probe. The lat- 
ter, consisting of a 972 bp fragment (base pairs 1573-2544, see 
[4]), was prepared by double digestion of the LDL receptor 
cDNA clone pLDLR3 (kindly provided by Dr D.W. Russell) 
with the enzymes XhoI and BarnHI and subsequent recovery of 
the fragment from the 0.6% agarose gel. Labelling of the probe 
was accomplished by a random oligonucleotide priming techni- 
que using a commercial kit (Amersham). After hybridization 
for 20 h at 42’-‘C, the filters were washed with 2 x SSC/O.l% 
SDS at room temperature and 0.2 x SSC/O.l% SDS at 50°C. 
Autoradiography of the dried filters was conducted by exposing 
them to Kodak XAR films for 2-5 days at -70°C. 
3. RESULTS 
When DNA from healthy controls was digested 
with PvuII, fractionated on 0.6% agarose, 
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Fig. 1. Autoradiogram of PvuII-digested DNA samples. 
hybridized with the ‘*P-1abelled LDL receptor gene probe. 
Lanes: l-4, samples from healthy controls; 5-9, samples from 
FH patients. An abnormal 11 kb PvuII fragment is present in 
samples 5,8. 
Table 1 
PvuII genotypes of control subjects and FH patients 
P-/P- P-/P+ P+/P+ P-/l1 kbP+/ll kb 
Controls 
(n = 51) (5Zo) (3:to) (l&o) - 
_ 
FH 
(n = 52) (3go) (2&) &o) (2:io) 
3 
(6%) 
P- indicates the absence of the PvuII restriction site (16 kb 
fragment) and P + its presence (14 kb fragment) 
transferred to nitrocellulose and subsequently 
hybridized with the LDL receptor probe, a restric- 
tion fragment length polymorphism (RFLP) 
became evident (fig.1). This RFLP is due to a 
variable PvuII site within intron 15 of the receptor 
gene [ 18,191. The absence of the PvuII site resulted 
in the appearance of a 16 kb restriction fragment 
whereas its presence produced a 14 kb fragment 
(fig.1). When DNA from FH patients was ana- 
lyzed in the same way, the same polymorphism was 
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Fig.2. Restriction enzyme mapping of the LDL receptor gene 
mutation. (A) Autoradiogram of DNA samples from a patient 
with FH (left of each sample pair) and a control subject (right 
of each sample pair), digested with PvuII (P), NcoI (N), EcoRV 
(E), BarnHI (B) and 7x301 (X), and hybridized with the 32P- 
labelled LDL receptor gene probe. In each case, the abnormal 
restriction fragment revealed in the patient’s DNA is designated 
by an arrow. (B) Restriction map of the 3’-end of the LDL 
receptor gene ([15,20] and data provided by Dr D.W. Russell) 
from a healthy subject (above) and a Finnish patient with FH 
(below). Exons are denoted by numbering. The 5’- and 
3 ‘-boundaries of the cDNA probe employed are indicated 
uppermost. The polymorphic PvuII restriction site is indicated 
by an asterisk. Suggested location of the deletion is indicated by 
broken lines. 
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detected, but a unique 11 kb fragment was found 
in DNA samples from 16 (31%) out of the 52 FH 
cases examined (fig. 1). 
The PvuII genotypes of the controls and FH pa- 
tients are summarized in table 1 where P + denotes 
the presence of the PvuII site and P - its absence. 
No FH patient homozygous for the 11 kb frag- 
ment was found. 
To characterize further the mutation that gives 
rise to the abnormal 11 kb PvuII fragment, DNAs 
from FH patients carrying the unique allele and 
controls were analyzed by Southern blotting using 
the enzymes BamHI, EcoRV, NcoI and XbaI. 
Representative xamples of the results are shown 
in fig.2. Collectively, restriction mapping data sug- 
gest that the mutation arose from a deletion of 
about 8 kb at the 3’-end of the LDL receptor gene. 
Southern blotting of genomic DNA does not per- 
mit a precise determination of the 5 ’ - and 
3 ‘-boundaries of this deletion. The most plausible 
interpretation of the data is that the deletion 
eliminates exons 16 and 17 and probably also a 
portion of the 5’-end of exon 18 (fig.2). 
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Fig.3. Demonstration of co-segregation of the FH phenotype 
with the deleted allele in a family. DNA was digested with PvuII 
and hybridized with the ‘*P-1abelled LDL receptor gene probe. 
Lanes: 1 (genotype P+/P -) and 2-4 (genotype P-/P-), 
DNA from healthy controls; 5,6 (genotype P- /ll kb), DNA 
from two unrelated patients with heterozygous FH. Family with 
FH - lanes: 7, healthy mother (genotype P-/P-); 8, child 
with FH (genotype P- /ll kb); 9, child with FH (genotype 
P - /I1 kb); 10, father with FH (genotype P + /ll kb). 
The inheritance of the deleted LDL receptor 
gene was followed in three informative families. 
An example of these studies is shown in fig.3. An 
unequivocal co-segregation of hyper- 
cholesterolemia with the mutant allele was found 
in each family investigated. 
4. DISCUSSION 
This study demonstrates that a specific type of 
mutation of the LDL receptor gene is involved in 
about one-third of Finns with the heterozygous 
form of familial hypercholesterolemia. The muta- 
tion deletes about 8000 base pairs from the 3 ’ -end 
of the LDL receptor gene. The mutated allele may 
be expected to encode a truncated receptor protein 
lacking the membrane spanning region and the 
cytoplasmic tail of the receptor [5]. 
Large deletions between exons 12 and 18 have 
been described in occasional patients with FH 
[7,10,13,21,22]. Whether the Finnish type of muta- 
tion represents one of those reported previously 
awaits further studies in which the mutated gene is 
cloned and sequenced. 
Characterization of the mutation by haplotype 
studies with the aid of a published database [23] is 
hampered by the fact that no Finnish patient 
homozygous for the deleted allele was found. Very 
recently, we were able to investigate DNA from a 
Finnish patient with homozygous familial hyper- 
cholesterolemia. This patient proved to have one 
deleted allele, similar to that found in the 
heterozygotes in the present study, and one allele 
with no gross abnormalities, thus representing a 
genetic compound (Aalto-Set&i, K. et al., un- 
published). 
With the exception of a few populations, muta- 
tions from families to families are different. The 
‘Lebanese allele’ is responsible for the extraor- 
dinarily high incidence of FH in Lebanon and is 
biochemically attributable to a single nucleotide 
substitution that creates a premature termination 
codon at amino acid 660, eliminating 180 residues 
from the carboxyl end of the mature protein [12]. 
A large deletion eliminating the promoter region 
and the first exon of the LDL receptor gene occurs 
in 63% of French Canadians with heterozygous 
FH, providing an effective diagnostic means in this 
population [ 151. Haplotype analysis of DNA from 
FH patients among South African Afrikaners 
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similarly demonstrates a founder gene effect in this 
population; the predominant mutation involved 
awaits, however, more detailed characterization 
[16]. It is of note that in other populations gross 
mutations, such as large deletions, of the LDL 
receptor gene represent only a minority (3-6%) of 
the spectrum of mutations (Langlois, P. and Hum- 
phries, S., papers presented at the International 
Symposium on Familial Hypercholesterolemia, 
Oslo, August 28-29, 1987). Our preliminary 
findings suggest that, with the exception of the 
mutation described here, no other type of major 
LDL receptor gene alterations occurs in Finns. 
An explanation for the enrichment of a specific 
LDL receptor gene mutation in Finland may be 
sought via historical, geographical and linguistic 
arguments [24]. Relatively few ancestor Finns 
originally inhabited the south-western part of the 
country during the first centuries AD. The increase 
in population was very slow up to the 16th and 
17th century when effective inhabitation of other 
parts of the country commenced. At no time did 
any significant immigration from Sweden or 
Russia occur. A major barrier against both west 
and east has been the Finnish language, bearing no 
philological resemblance to any major class of 
languages. It is thus not surprising that Finland has 
its own peculiar panel of inherited diseases and vir- 
tually lacks other inherited diseases (e.g. 
phenylketonuria, cystic fibrosis and thalassemias) 
which are rather common in other parts of the 
world [24]. The exact prevalence of FH in Finland 
is not known. 
The practical benefits of the present data are ob- 
vious. A simple and definitive diagnosis by DNA 
methods can be offered to about one-third of Fin- 
nish patients with FH. In the affected families, in- 
heritance of the disease can be easily traced from 
generation to generation. It remains to be in- 
vestigated whether the same type of LDL receptor 
gene mutation occurs in other European 
populations. 
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